These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 17761999)
1. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Eurich DT; McAlister FA; Blackburn DF; Majumdar SR; Tsuyuki RT; Varney J; Johnson JA BMJ; 2007 Sep; 335(7618):497. PubMed ID: 17761999 [TBL] [Abstract][Full Text] [Related]
2. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Eurich DT; Weir DL; Majumdar SR; Tsuyuki RT; Johnson JA; Tjosvold L; Vanderloo SE; McAlister FA Circ Heart Fail; 2013 May; 6(3):395-402. PubMed ID: 23508758 [TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Masoudi FA; Inzucchi SE; Wang Y; Havranek EP; Foody JM; Krumholz HM Circulation; 2005 Feb; 111(5):583-90. PubMed ID: 15699279 [TBL] [Abstract][Full Text] [Related]
4. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. Hippisley-Cox J; Coupland C BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012 [TBL] [Abstract][Full Text] [Related]
5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
6. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Fisman EZ; Tenenbaum A; Benderly M; Goldbourt U; Behar S; Motro M Cardiology; 1999; 91(3):195-202. PubMed ID: 10516414 [TBL] [Abstract][Full Text] [Related]
7. Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study. Giorda CB; Picariello R; Tartaglino B; Marafetti L; Di Noi F; Alessiato A; Costa G; Gnavi R BMJ Open; 2015 Jun; 5(6):e007959. PubMed ID: 26048211 [TBL] [Abstract][Full Text] [Related]
8. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. Ou HT; Chang KC; Li CY; Wu JS Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742 [TBL] [Abstract][Full Text] [Related]
9. Neither diabetes nor glucose-lowering drugs are associated with mortality after noncardiac surgery in patients with coronary artery disease or heart failure. Hanninen M; McAlister FA; Bakal JA; van Diepen S; Ezekowitz JA Can J Cardiol; 2013 Apr; 29(4):423-8. PubMed ID: 22985785 [TBL] [Abstract][Full Text] [Related]
10. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648 [TBL] [Abstract][Full Text] [Related]
11. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Krentz AJ; Bailey CJ Drugs; 2005; 65(3):385-411. PubMed ID: 15669880 [TBL] [Abstract][Full Text] [Related]
12. [Which antidiabetic agent in a patient with type 2 diabetes and heart failure ?]. Scheen AJ; Paquot N Rev Med Liege; 2017 Sep; 72(9):423-428. PubMed ID: 28892319 [TBL] [Abstract][Full Text] [Related]
13. Type 2 diabetes mellitus and heart failure. Choy CK; Rodgers JE; Nappi JM; Haines ST Pharmacotherapy; 2008 Feb; 28(2):170-92. PubMed ID: 18225964 [TBL] [Abstract][Full Text] [Related]
14. Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta-analysis. Phung OJ; Baker WL; Tongbram V; Bhardwaj A; Coleman CI Ann Pharmacother; 2012 Apr; 46(4):469-76. PubMed ID: 22474136 [TBL] [Abstract][Full Text] [Related]
15. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. Weir DL; McAlister FA; Senthilselvan A; Minhas-Sandhu JK; Eurich DT JACC Heart Fail; 2014 Dec; 2(6):573-82. PubMed ID: 24998080 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study. Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814 [TBL] [Abstract][Full Text] [Related]
17. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic. Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426 [TBL] [Abstract][Full Text] [Related]
18. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Karter AJ; Ahmed AT; Liu J; Moffet HH; Parker MM Diabet Med; 2005 Aug; 22(8):986-93. PubMed ID: 16026362 [TBL] [Abstract][Full Text] [Related]